ESMO 2022: Summary of ESMO Adjuvant RCC Trials
Axel Bex summarizes the RCC studies that were presented at ESMO 2022, including potential toxicity of ipilimumab/nivolumab, pembrolizumab response rates, and single-agent atezolizumab versus placebo.
670 Madison Ave.
Manalapan, NJ 07726
Contributors and Partners
Cancer Nursing Today
Urban Health Today
Blood Cancers Today
© 2022 Mashup Media, LLC. All rights reserved.